Clinical trials: Hyperhidrosis
HYPERHIDROSIS
Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT01810991
- Testing
- Nd:YAG Laser
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.
- Trial name
- NCT02479139
- Testing
- Vehicle, ANT-1207
- Where
- 19 sites in United States
- Volunteers
- 145 people
- Sponsor
- Allergan
Hyperhidrosis Primary Focal Axilla
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF.
- Trial name
- NCT05860972
- Testing
- Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
- Where
- 4 sites in United States, Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
Hyperhidrosis
Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Treatment of primary hyperhidrosis through a comparative study between oxybutynin hydrochloride and placebo. Hydrochloride may decrease the symptoms of hyperhidrosis improving the subject's quality of life.
- Trial name
- NCT02099695
- Testing
- Oxybutynin
- Where
- 2 sites in Brazil
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Hyperhidrosis
Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis
Up to 20 subjects will be treated. Subjects will receive two (2) bilateral Ultherapy™ or Sham treatments of the axilla. The study hypothesis is that subjects who receive Ultherapy™ treatment will have a greater reduction in…
- Trial name
- NCT01713673
- Testing
- Ulthera System Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ulthera, Inc
Hyperhidrosis
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks…
- Trial name
- NCT02129660
- Testing
- Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD
- Where
- 15 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Journey Medical Corporation
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
This is a three-year study in subjects with axillary hyperhidrosis involving injection of Botulinum Toxin Type A into the axilla to reduce sweating.
- Trial name
- NCT00168402
- Testing
- Botulinum Toxin Type A
- Volunteers
- 193 people
- Sponsor
- Allergan
Primary Focal Hyperhidrosis, Axilla
Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis
This is a prospective, multi-center, parallel, randomized, blinded study. The study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the DTS-G2…
- Trial name
- DRI-UP (NCT00931359)
- Testing
- DTS-G2 System
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Miramar Labs
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
- Trial name
- NCT02565732
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Revance Therapeutics, Inc.